We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

81 hedge funds and large institutions have $47.1M invested in Ovid Therapeutics in 2025 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 17 increasing their positions, 24 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

297% more capital invested

Capital invested by funds: $11.9M → $47.1M (+$35.2M)

79% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 14

14% more funds holding

Funds holding: 71 → 81 (+10)

0.35% more ownership

Funds ownership: 50.58% → 50.92% (+0.35%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

29% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 24

34% less call options, than puts

Call options by funds: $299K | Put options by funds: $456K

Holders
81
Holders Change
+10
Holders Change %
+14.08%
% of All Funds
1.06%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
25
Increased
17
Reduced
24
Closed
14
Calls
$299K
Puts
$456K
Net Calls
-$157K
Net Calls Change
-$162K

Top Buyers

Rank Fund Capital Flow
1
AAA
Affinity Asset Advisors
New York
+$1.72M
2
IC
Ikarian Capital
Texas
+$950K
3
SSA
Schonfeld Strategic Advisors
New York
+$765K
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$542K
5
Marshall Wace
Marshall Wace
United Kingdom
+$536K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$1.27M
2
SCM
Sio Capital Management
New York
-$697K
3
BlackRock
BlackRock
New York
-$657K
4
TA
TLS Advisors
Florida
-$574K
5
MAP
Madison Avenue Partners
New York
-$433K
Name Holding Trade Value Shares
Change 		Change in
Stake
GCP
26
GSA Capital Partners
United Kingdom
$346K -$413K -476,197 -64%
Jane Street
27
Jane Street
New York
$310K +$83K +95,818 +67%
UBS Group
28
UBS Group
Switzerland
$309K +$187K +216,310 +998%
State Street
29
State Street
Massachusetts
$295K – – –
PHP
30
Parkman Healthcare Partners
Connecticut
$264K +$176K +202,978 New
Group One Trading
31
Group One Trading
Illinois
$245K +$163K +188,295 New
DP
32
Diadema Partners
New Jersey
$244K +$163K +187,739 New
XT
33
XTX Topco
Cayman Islands
$238K +$90.9K +104,878 +134%
VCIM
34
Velan Capital Investment Management
Georgia
$208K – – –
Two Sigma Advisers
35
Two Sigma Advisers
New York
$197K +$132K +151,800 New
Northern Trust
36
Northern Trust
Illinois
$197K +$45.6K +52,593 +53%
Squarepoint
37
Squarepoint
New York
$149K -$92K -106,203 -48%
BCM
38
Bridgeway Capital Management
Texas
$124K – – –
EF
39
Empowered Funds
Pennsylvania
$119K – – –
CSS
40
Cubist Systematic Strategies
Connecticut
$113K +$71.7K +82,778 +2,137%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$75K +$1 +1 +0%
IWC
42
Integrated Wealth Concepts
Massachusetts
$68.8K +$45.8K +52,900 New
Fidelity Investments
43
Fidelity Investments
Massachusetts
$61.1K -$1 -1 -0%
PAP
44
Persistent Asset Partners
Hong Kong
$59.9K +$39.9K +46,040 New
AHL
45
Abel Hall LLC
Louisiana
$42.1K – – –
Goldman Sachs
46
Goldman Sachs
New York
$37.1K -$221K -255,307 -90%
QC
47
Quadrature Capital
United Kingdom
$35.9K +$24K +27,703 New
AWM
48
Apollon Wealth Management
South Carolina
$35.8K +$23.8K +27,500 New
First Manhattan
49
First Manhattan
New York
$33.8K – – –
PAG
50
Private Advisor Group
New Jersey
$33.3K +$22.2K +25,600 New
1
2
3 4

OVID Hedge Fund Activity: Q3 2025 in Review

81 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q3 2025, worth a combined $47.1M — up 297% from $11.9M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new OVID positions and 14 closed out — a net gain of 11 holders — while 17 added to existing stakes and 24 trimmed.

The largest buyer was Affinity Asset Advisors, adding an estimated $1.72M. The largest seller was BVF Inc, exiting entirely with an estimated $1.27M sold.

  • 81 institutional investors held Ovid Therapeutics (OVID) as of Q3 2025, up from 71 in Q2 2025.
  • Funds reported $47.1M of Ovid Therapeutics stock for Q3 2025, up 297% quarter-over-quarter.
  • 25 funds opened new Ovid Therapeutics positions in Q3 2025 and 14 closed out, a net change of +11 holders.
  • The largest Ovid Therapeutics buyer in Q3 2025 was Affinity Asset Advisors, an estimated $1.72M added.
  • The largest Ovid Therapeutics seller in Q3 2025 was BVF Inc, an estimated $1.27M sold.

Based on aggregated 13F filings for Q3 2025.